Novel Agents for the Treatment of Crohn's Disease

Novel Therapies for Crohn's Disease: Focus on Immunomodulators ...

To review the literature on novel immunomodulators such as tumor necrosis factor alpha (TNF-α)- and interleukin (IL)-related agents, 6-thioguanine (6-TG), ...

Vedolizumab as Induction and Maintenance Therapy for Crohn's ...

Crohn's disease is a chronic inflammatory bowel disease. ... Current treatments include glucocorticoids, immunosuppressive agents (i.e., ...

Current status of novel biologics and small molecule drugs in the ...

Anti-TNF agents were the first class of biologics to be approved for IBD treatment, and since then, they have tremendously changed IBD ...

Novel Therapies for Patients With Inflammatory Bowel Disease

Vedolizumab (Entyvio, Takeda) and ustekinumab (Stelara, Janssen) also represent well-studied biologic agents that have been approved for patients with IBD.7-10 ...

Novel Drug Therapies for the Treatment of Crohn's Disease

Expert opinion: Anti-TNF agents will remain the mainstay of biological therapy in in Crohn's disease in the near future. However; the proportion of anti-TNF ...

Systematic Review with Network Meta‐Analysis: Efficacy of ...

The optimal management of such patients is not clearly defined. Besides traditional anti-TNF agents (infliximab, adalimumab, and certolizumab), ...

Advances in the treatment of Crohn's disease - Gastroenterology

In some of these trials, the biologic agents performed better than placebo, and, without doubt, these results constitute the major advances in the medical ...

IBD therapeutics: what is in the pipeline? - Frontline Gastroenterology

Novel therapies · JAK-STAT inhibitors · Selective lymphocyte trafficking inhibitors · IL12/IL23 inhibitors · S1P receptor modulators.

PRIME® Personalizing the Care of IBD Through Novel Treatments ...

The myriad of available therapies for inflammatory bowel disease (IBD), as well as the numerous agents under development, can create challenges in selecting the ...

S3960 Triple Agent Therapy as a Novel Approach to Inflammatory ...

Inflammatory Bowel Disease (IBD) therapies include corticosteroids, 5-aminosalicylates, immunomodulators, biologics, and small molecules. Our case report ...

Modern Advanced Therapies for Inflammatory Bowel Diseases

Currently, 2 IL23 antagonists are approved by the FDA: risankizumab for moderate-severe CD, and mirikizumab for moderate-severe UC; these drugs, ...

Novel IBD Interventions

Treatment · Corticosteroids (i.e., prednisone and budesonide) · Antibiotics · Immunomodulators (i.e., azathioprine, 6-mercaptopurine, and methotrexate) · The Food ...

Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe ...

interleukin agents approved for Crohn's disease. As the experience with risankizumab as the treatment for Crohn's disease is still in its nascency, it is ...

UC Davis Health leads study on promising stem cell-based therapy ...

... for Crohn's disease ... medications to offer relief from common ... novel therapies that induce sustained remission with minimal side effects to ...

Medications for Crohn's Disease: Types and Examples

These include drugs such as aminosalicylates, steroids, and antibiotics. Other novel treatments approved in recent years include biologics and ...

Novel treatments for inflammatory bowel disease - of DSpace

Among these, vedolizumab has recently been approved for both Crohn's disease and ulcerative colitis. ... These agents will likely expand the treatment options ...

Improving IBD outcomes in the era of many treatment options - Nature

Head-to-head comparison of adalimumab and ustekinumab in moderately to severely active Crohn's disease in the SEAVUE study showed that their ...

cyclosporine therapy in the management of inflammatory bowel ...

Cyclosporine has progressed from strictly a transplant drug, to a novel therapeutic agent for the management of inflammatory bowel disease (IBD) ...

Medical management of moderate to severe Crohn disease in adults

Outline · Anti-TNF agent monotherapy · Anti-interleukin antibody therapy · Anti-integrin antibody therapy · Janus kinase (JAK) inhibitor therapy.

Dual Advanced Therapies and Novel Pharmacotherapies for ...

Dual advanced therapies (combination of biologics and/or small molecule therapies) have been used to treat refractory Crohn's disease and/or concomitant ...